Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Q&A: Nipple-Sparing Mastectomy After Breast Radiation

2.

Vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

3.

What is Mohs micrographic surgery? 8 FAQs about Mohs

4.

Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma

5.

An understudied type of breast cancer poses a lurking threat


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot